Demand for Enlarged Prostate Treatments Expected to Rise Sharply.

Positive Trial Results for Nymox's (NASDAQ:NYMX) NX-1207 Drug Treatment for Enlarged Prostate 

HASBROUCK HEIGHTS, N.J. -- Changing demographics and attitudes towards health will drive the demand for new and effective treatments for enlarged prostate in the maturing male baby boomer population, according to Brian Doyle, Senior Manager for Worldwide Sales and Marketing for Nymox Pharmaceutical Corporation (NASDAQ:NYMX). Enlarged prostate or benign prostatic hyperplasia (BPH) is currently the fourth most commonly diagnosed ailment of men over the age of 50 in the U.S. (Am J Manag Care. 2006;12(4 Suppl):S83-9). In 2000 alone approximately 4.5 million visits were made to physician offices for a primary diagnosis of BPH (Urological Diseases in America Chapter 2, Benign Prostatic Hyperplasia, National Institutes of Health). This number is expected to rise sharply as the men of the baby boomer generation enter their 50s and 60s.

Nymox has developed NX-1207, an innovative new treatment for BPH. The company's recently completed Phase 2 trial showed positive efficacy and safety results for NX-1207. Overall, patients treated with NX-1207 showed mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 point reported in published studies of currently approved drugs for BPH and reached statistical significance when compared to placebo. Subjects treated with NX-1207 also showed an overall significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects. Serious adverse events occurred in 5.1% of all placebo patients, and in 0% of the NX-1207 treated group.

"The demand for effective treatments for BPH will be driven not only by the increase in the total number of men with BPH but also by the changing attitudes towards health in the baby boomer generation," said Brian Doyle. "Increasingly, men enter their 50s and 60s expecting to maintain their level of health and activity. BPH represents a challenge to those expectations, both in terms of lifestyle and physical health. Current treatments either are not very effective or carry risks of serious side effects or both. There is a pressing unmet need for a convenient and effective treatment of this common affliction of men."

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.